BioSpace News Archive

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that management will present at the following upcoming investor conferences:

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced the appointment of Steve Morris, M.D. as Chief Medical Officer.

Indegene, a technology-led healthcare solutions provider announced the appointment of Pankaj Kakkar, former Head of Healthcare Provider Delivery at Tech Mahindra to strengthen its Global Operations.

Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2021 .

Karuna Therapeutics, Inc. announced that senior management will participate in the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:00 a.m. ET.

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021 .

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its novel product PEMFEXY™ (pemetrexed for injection).

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company’s Executive Committee, effective February 1, 2022.

Microbix Biosystems Inc. announces the expansion of its portfolio of Quality Assessment Products to include a swab-formatted control that helps validate the accuracy and integrity of the workflows of nucleic-acid based tests for SARS-CoV-2 Wuhan strain and the Omicron variant – the latter now being the most prevalent form of COVID.

PharmaTher Holdings Ltd. is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) for ketamine to treat Status Epilepticus (“SE”), a rare neurological disorder requiring emergency treatment for a seizure.